Four vaccines have entered clinical phase 3 in China, and 60000 people have been vaccinated without serious adverse reactions

category:Hot
 Four vaccines have entered clinical phase 3 in China, and 60000 people have been vaccinated without serious adverse reactions


On October 15 local time, the lancet, an international authoritative academic journal, published on its official website the latest results of a clinical trial of Chinas new crown vaccine.

Previously, the Wuhan Institute of biological products published the worlds first clinical trial data of new crown inactivated vaccine published in the Journal of American Medical Association.

According to the introduction, bbibp CorV new crown inactivated vaccine was jointly developed by Henan Provincial Center for Disease Control and prevention, China biological Beijing Institute of biological products and China Center for Disease Control and prevention.

In addition, the strains used in this study were from three patients in Wuhan, Chongqing and Qingdao. The vaccine used in the trial was divided into three test doses, namely, 2 u03bc g (low), 4 u03bc g (medium) and 8 u03bc g (high). The trial was divided into random group, double-blind group and placebo control group.

Phase I and phase II clinical trials have good safety and immunogenicity, and are safe and effective for the elderly

The results of this trial showed that bbibp CorV new crown inactivated vaccine was safe and well tolerated in both age groups. After 42 days of vaccination, all the vaccinators had high level of McAb, including those over 60 years old with weak immune function, which provided valuable data for the elderly population.

In the phase II study, 448 healthy adults (18-59 years old) were divided into four groups and received high-dose vaccine or placebo on day 0, or medium dose vaccine or placebo on day 0 / 14, day 0 / 21, or day 0 / 28, respectively. The safety and tolerability were mainly evaluated, and the secondary outcome was immunogenicity, which was evaluated as a neutralizing antibody response to infectious sars-cov-2.

The results of this experiment showed that high neutralizing antibody titer could be obtained by inoculating twice with medium dose each time, and the interval was 21 or 28 days. The control group with all two injections was better than the single vaccination.

This result shows that the vaccine can effectively induce neutralizing antibody in this age group, and the level of neutralizing antibody is similar to that reported in other vaccine studies, which proves that the vaccine has good immunogenicity.

In the phase I study, 192 people were randomly assigned to receive different doses of vaccine or placebo. Among the 144 vaccinators, 42 (29%) had adverse reactions in the first 7 days after vaccination, mainly manifested in pain at the vaccination site, followed by fever, but all of them were mild or moderate. No serious adverse reactions were observed within 28 days of vaccination.

It can be concluded that bbibp CorV new crown inactivated vaccine is safe and well tolerated in both age groups.

Chinas new crown vaccine research and development progress is the worlds leading, will make a great contribution to the global anti epidemic

In its report agency, Reuters reported that antibodies could be produced in every group of vaccinators, including the elderly, in the bbibp CorV new crown inactivated vaccine trial. In addition to this vaccine, China Biotechnology Group Corporation (China Biology), a subsidiary of China Pharmaceutical Group Co., Ltd., has another candidate vaccine, which is currently undergoing phase III trials overseas.

According to the information previously disclosed by the World Health Organization (who), at least 10 new coronal vaccine projects have entered the phase III trial stage, of which 4 projects are led by Chinese scientists.

According to China biology, the bbibp CorV new crown inactivated vaccine developed by Beijing Institute of biological products was approved by the State Food and Drug Administration on April 27, and phase I and phase II clinical trials were started simultaneously.

At present, the Beijing Institute of biological products and Wuhan Institute of biological products affiliated to the Chinese Institute of biological products are promoting phase III clinical trials in UAE, Bahrain, Egypt, Morocco, Peru, Argentina and other countries in an orderly manner. The sample population now covers 125 countries, and the progress in all aspects is leading the world.

Last month, the UAE health minister was inoculated with the new crown vaccine developed by China (UAE news agency)

Chinas China novel coronavirus pneumonia spokesman Hua Chunying said in October 9th that China had signed an agreement with the global alliance for vaccines and immunization on 8 th, and formally joined the new crown vaccine program (COVAX). This is an important measure for China to uphold the concept of the community of human health and fulfill its own commitments to promote vaccine to become a global public product.

(function(){( window.slotbydup=window .slotbydup||[]).push({id:u5811557,container:ssp_ 5811557, async:true }Ayelet Berman, a senior researcher at the center for international law at the National University of Singapore, said Chinas participation may bring huge financial support to the program, and Chinas potential to provide vaccines and production capacity for the program will have a positive impact on global vaccine access. Chinas participation in novel coronavirus pneumonia vaccine implementation plan is also a great achievement, Bloomberg said. Because even the possibility of providing vaccines to a small proportion of Chinas 1.4 billion population will increase the critical production of vaccines, thus enhancing the alliances negotiating power. In addition, it wrote in its report that Chinas accession fills the gap in global health leadership in this field after trump rejected the plan and Chinas move has formed a positive contrast with the United States. Source: Beijing daily client editor: Yu changzong_ NBJ11145

Ayelet Berman, a senior researcher at the center for international law at the National University of Singapore, commented that Chinas participation may bring huge financial support to the program, and that Chinas potential to provide vaccines and production capacity for the program will have a positive impact on global vaccine acquisition.

Chinas participation in novel coronavirus pneumonia vaccine implementation plan is also a great achievement, Bloomberg said. Because even the possibility of providing vaccines to a small proportion of Chinas 1.4 billion population will increase the critical production of vaccines, thus enhancing the alliances negotiating power.

In addition, it wrote in its report that Chinas accession fills the gap in global health leadership in this field after trump rejected the plan and Chinas move has formed a positive contrast with the United States.